GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for advanced cancers: experimental drug enters human trials
Disease control Recruiting nowThis study tests a new drug, BMS-986340, alone or with other cancer treatments (nivolumab or docetaxel) in people with advanced solid tumors that have worsened after standard therapy. The goal is to find safe doses and understand side effects. About 949 adults with various cancer…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New drug KIVU-107 targets tough tumors in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug, KIVU-107, in about 76 adults with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goal is to find the…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC